VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease

Shaney L. Barratt*, Victoria A. Flower, John D. Pauling, Ann B. Millar

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)peer-review

41 Citations (Scopus)
252 Downloads (Pure)


Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease.

Original languageEnglish
Article number1269
Number of pages17
JournalInternational Journal of Molecular Sciences
Issue number5
Early online date24 Apr 2018
Publication statusPublished - 1 May 2018

Bibliographical note

Special Issue: Vascular Endothelial Growth Factor


  • Fibrosis
  • Interstitial lung disease
  • Vascular endothelial growth factor
  • VEGF


Dive into the research topics of 'VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease'. Together they form a unique fingerprint.

Cite this